MissionIR would like to highlight CytRx Corp. (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology. The company’s pipeline is focused on the clinical development of aldoxorubicin (formerly known as INNO-206), its improved version of the widely used chemotherapeutic agent doxorubicin. The Company also has rights to two additional drug candidates, tamibarotene and bafetinib.
In the company’s news,
Seeking Alpha yesterday published the following article featuring CytRx: http://seekingalpha.com/article/1700372-cytrx-corporation-remains-an-undiscovered-opportunity-inthe-cancer-space?source=yahoo#comments_header
Released On: 4/8/2016
Views: 3827
Released On: 4/7/2016
Views: 4566
Released On: 3/31/2016
Views: 3539
Released On: 3/24/2016
Views: 2899
Released On: 3/17/2016
Views: 2455
Released On: 3/11/2016
Views: 2279
Released On: 3/4/2016
Views: 2595
Released On: 3/3/2016
Views: 2291
Released On: 2/23/2016
Views: 3645
Released On: 2/12/2016
Views: 2642
Released On: 2/10/2016
Views: 2348
Released On: 2/9/2016
Views: 2508
Released On: 1/20/2016
Views: 4287
Released On: 1/14/2016
Views: 4749
Released On: 1/5/2016
Views: 2998
Released On: 12/18/2015
Views: 9309
Released On: 12/9/2015
Views: 2754
Released On: 12/3/2015
Views: 3187